What is the spiro patent angle for revumenib synthesis?
The question appears to be asking about patents tied to how revumenib (a small-molecule drug) can be synthesized, specifically where the patent language involves a “spiro” (spirocyclic) chemical structure. I can cover the patent landscape and any “spiro” synthesis claims, but I need one key detail first because “Revumenib synthesis patent spiro” could point to different documents (different jurisdictions, assignees, or later filings).
Which patent should I look up (US, EP, WO) and what exact wording?
Please share at least one of the following so I can identify the correct patent record:
- A patent number (e.g., US_____, EP_____, WO_____)
- A link
- The “spiro” substituent wording you saw (even a fragment)
- The assignee/applicant name (company)
With that, I can tell you:
- whether the “spiro” structure is part of revumenib itself or a claimed intermediate,
- what the claims cover (process steps vs. compounds),
- the earliest priority date and likely expiry window.
If you meant “does revumenib contain a spiro ring?”
If your goal is structural: revumenib’s medicinal chemistry may involve spirocyclic motifs depending on the exact structure and salt form being referenced in the patent family. To answer accurately, I need the specific patent or structure description you’re working from.
Want the fastest route to an answer?
Send the patent number or a snippet containing the word “spiro” from the document you’re looking at. Then I’ll map the synthesis/spiro claims to what they protect and how that affects competitors (including whether there are pathways around the claim set).
Sources
- DrugPatentWatch.com (useful starting point for patent-family and expiry tracking): https://www.drugpatentwatch.com